INTERNATIONAL JOURNAL OF COLORECTAL DISEASE, ISSN 0179-1958, 03/2016, Volume 31, Issue 3, pp. 725 - 726
To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s00384-015-2221-y
SURGERY | GASTROENTEROLOGY & HEPATOLOGY | Crohn Disease - therapy | Perineum - pathology | Mesenchymal Stromal Cells - cytology | Humans | Adult | Platelet-Rich Plasma - metabolism | Mesenchymal Stem Cell Transplantation | Tissue engineering | Surgery, Plastic | Stem cells
SURGERY | GASTROENTEROLOGY & HEPATOLOGY | Crohn Disease - therapy | Perineum - pathology | Mesenchymal Stromal Cells - cytology | Humans | Adult | Platelet-Rich Plasma - metabolism | Mesenchymal Stem Cell Transplantation | Tissue engineering | Surgery, Plastic | Stem cells
Journal Article
International Journal of Colorectal Disease, ISSN 0179-1958, 3/2016, Volume 31, Issue 3, pp. 725 - 726
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7, p. e0182009
Adoptive transfer of CD4+CD25+FOXP3+regulatory T cells (Treg cells) has been successfully utilized to treat graft versus host disease and represents a...
MAMMALIAN TARGET | FOXP3 EXPRESSION | IN-VITRO | TGF-BETA | MULTIDISCIPLINARY SCIENCES | EXPANSION | CD4(+) | INDUCTION | IL-2 RECEPTOR | EX-VIVO | VITAMIN-A | Forkhead Transcription Factors - immunology | T-Lymphocytes, Regulatory - metabolism | Humans | T-Lymphocytes, Regulatory - immunology | Young Adult | Flow Cytometry | Interleukin-2 Receptor alpha Subunit - genetics | T-Lymphocytes - metabolism | Forkhead Transcription Factors - metabolism | T-Lymphocytes - drug effects | Adult | Antineoplastic Agents - pharmacology | Transforming Growth Factor beta1 - pharmacology | Interleukin-2 Receptor alpha Subunit - immunology | Tretinoin - pharmacology | Cells, Cultured | Forkhead Transcription Factors - genetics | Sirolimus - pharmacology | Drug Synergism | T-Lymphocytes, Regulatory - drug effects | Interleukin-2 Receptor alpha Subunit - metabolism | Adolescent | CpG Islands - genetics | Interleukin-2 - pharmacology | T-Lymphocytes - immunology | DNA Methylation - drug effects | Cell proliferation | Cell culture | Graft-versus-host reaction | Transplants & implants | Effector cells | Lymphocytes T | Assaying | Adoptive transfer | Homing | Conserved sequence | Interleukin 2 | Lymphocytes | DNA methylation | CD25 antigen | Foxp3 protein | Deoxyribonucleic acid--DNA | Antigens | Cytokines | Immunoregulation | Markers | Cultures | Rapamycin | Gene expression | CXCR4 protein | CD4 antigen | Graft rejection | Rejection | Acids | Human performance | Epigenetics | Methylation | Autoimmune diseases | In vitro methods and tests | Retinoic acid | Cell migration | Deoxyribonucleic acid | DNA
MAMMALIAN TARGET | FOXP3 EXPRESSION | IN-VITRO | TGF-BETA | MULTIDISCIPLINARY SCIENCES | EXPANSION | CD4(+) | INDUCTION | IL-2 RECEPTOR | EX-VIVO | VITAMIN-A | Forkhead Transcription Factors - immunology | T-Lymphocytes, Regulatory - metabolism | Humans | T-Lymphocytes, Regulatory - immunology | Young Adult | Flow Cytometry | Interleukin-2 Receptor alpha Subunit - genetics | T-Lymphocytes - metabolism | Forkhead Transcription Factors - metabolism | T-Lymphocytes - drug effects | Adult | Antineoplastic Agents - pharmacology | Transforming Growth Factor beta1 - pharmacology | Interleukin-2 Receptor alpha Subunit - immunology | Tretinoin - pharmacology | Cells, Cultured | Forkhead Transcription Factors - genetics | Sirolimus - pharmacology | Drug Synergism | T-Lymphocytes, Regulatory - drug effects | Interleukin-2 Receptor alpha Subunit - metabolism | Adolescent | CpG Islands - genetics | Interleukin-2 - pharmacology | T-Lymphocytes - immunology | DNA Methylation - drug effects | Cell proliferation | Cell culture | Graft-versus-host reaction | Transplants & implants | Effector cells | Lymphocytes T | Assaying | Adoptive transfer | Homing | Conserved sequence | Interleukin 2 | Lymphocytes | DNA methylation | CD25 antigen | Foxp3 protein | Deoxyribonucleic acid--DNA | Antigens | Cytokines | Immunoregulation | Markers | Cultures | Rapamycin | Gene expression | CXCR4 protein | CD4 antigen | Graft rejection | Rejection | Acids | Human performance | Epigenetics | Methylation | Autoimmune diseases | In vitro methods and tests | Retinoic acid | Cell migration | Deoxyribonucleic acid | DNA
Journal Article
Inflammatory Bowel Diseases, ISSN 1078-0998, 12/2014, Volume 20, pp. S74 - S75
Journal Article
Colorectal Disease, ISSN 1462-8910, 03/2018, Volume 20, Issue 3, pp. O68 - O75
Aim To describe the long‐term outcomes of adipose‐mesenchymal stem cells, platelet‐rich plasma and endorectal advancement flaps in patients with perineal...
stem cells | Crohn's disease | platelet‐rich plasma | fistula | inflammatory bowel disease | platelet-rich plasma | SURGERY | MUCOSAL ADVANCEMENT FLAP | PERIANAL FISTULAS | NATURAL-HISTORY | REPAIR | INFLAMMATORY-BOWEL-DISEASE | QUALITY-OF-LIFE | GASTROENTEROLOGY & HEPATOLOGY | Medicine, Experimental | Medical research | Transplantation | Gastrointestinal diseases | Stem cells | Therapy | Inflammatory bowel diseases | Mesenchyme | Vagina | Fistulae | Fistula | Patients | Crohns disease | Flaps | Intestine | Surgery | Skin & tissue grafts | Biological treatment | Platelets
stem cells | Crohn's disease | platelet‐rich plasma | fistula | inflammatory bowel disease | platelet-rich plasma | SURGERY | MUCOSAL ADVANCEMENT FLAP | PERIANAL FISTULAS | NATURAL-HISTORY | REPAIR | INFLAMMATORY-BOWEL-DISEASE | QUALITY-OF-LIFE | GASTROENTEROLOGY & HEPATOLOGY | Medicine, Experimental | Medical research | Transplantation | Gastrointestinal diseases | Stem cells | Therapy | Inflammatory bowel diseases | Mesenchyme | Vagina | Fistulae | Fistula | Patients | Crohns disease | Flaps | Intestine | Surgery | Skin & tissue grafts | Biological treatment | Platelets
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2017, Volume 12, Issue 7
Journal Article
Surgical Endoscopy, ISSN 0930-2794, 7/2014, Volume 28, Issue 7, pp. 2090 - 2096
Laparoscopic colorectal surgery (LCRS) has several advantages over open surgery, but LCRS has been associated with a higher rate of postoperative complications...
Obesity | Gynecology | Laparoscopic surgery | Medicine & Public Health | Surgery | Hepatology | Gastroenterology | Obese patients | Abdominal Surgery | Early complications | Colorectal surgery | Postoperative complications | Proctology | SURGERY | RISK-FACTORS | CANCER SURGERY | WOUND-INFECTION | SURGICAL COMPLICATIONS | RECTAL-CANCER | MORBIDITY | PREOPERATIVE RADIOTHERAPY | BODY-MASS INDEX | OPEN COLECTOMY | CLASICC TRIAL | Body Mass Index | Intensive Care Units | Obesity - complications | Humans | Middle Aged | Male | Laparoscopy | Case-Control Studies | Rectal Diseases - surgery | Operative Time | Colonic Diseases - surgery | Aged, 80 and over | Adult | Female | Aged | Chile | Postoperative Complications | Length of Stay - statistics & numerical data | Cohort Studies | Complications
Obesity | Gynecology | Laparoscopic surgery | Medicine & Public Health | Surgery | Hepatology | Gastroenterology | Obese patients | Abdominal Surgery | Early complications | Colorectal surgery | Postoperative complications | Proctology | SURGERY | RISK-FACTORS | CANCER SURGERY | WOUND-INFECTION | SURGICAL COMPLICATIONS | RECTAL-CANCER | MORBIDITY | PREOPERATIVE RADIOTHERAPY | BODY-MASS INDEX | OPEN COLECTOMY | CLASICC TRIAL | Body Mass Index | Intensive Care Units | Obesity - complications | Humans | Middle Aged | Male | Laparoscopy | Case-Control Studies | Rectal Diseases - surgery | Operative Time | Colonic Diseases - surgery | Aged, 80 and over | Adult | Female | Aged | Chile | Postoperative Complications | Length of Stay - statistics & numerical data | Cohort Studies | Complications
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 04/2017, Volume 376, Issue 16, pp. 1527 - 1539
In two randomized trials comparing the PCSK9 inhibitor bococizumab with placebo, bococizumab had no benefit with respect to major adverse cardiovascular events...
MEDICINE, GENERAL & INTERNAL | EVENTS | REDUCTION | STATIN THERAPY | REDUCING LIPIDS | PCSK9 | GENETIC-VARIANTS | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Life Sciences | Human health and pathology
MEDICINE, GENERAL & INTERNAL | EVENTS | REDUCTION | STATIN THERAPY | REDUCING LIPIDS | PCSK9 | GENETIC-VARIANTS | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Risk Factors | Male | Injections, Subcutaneous - adverse effects | Proprotein Convertase 9 - immunology | Hypercholesterolemia - drug therapy | Anticholesteremic Agents - adverse effects | Anticholesteremic Agents - immunology | Anticholesteremic Agents - therapeutic use | Proprotein Convertase 9 - antagonists & inhibitors | Lipids - blood | Treatment Failure | Antibodies - blood | Cholesterol, LDL - blood | Female | Antibodies, Monoclonal, Humanized - immunology | Myocardial infarction | Cerebral infarction | Lipoproteins (low density) | Immunoglobulins | Stroke | Risk groups | Clinical trials | Cardiovascular disease | Lipids | Subtilisin | Angina | Low density lipoprotein | Manuscripts | Cholesterol | Disease prevention | Kexin | Monoclonal antibodies | Cardiovascular diseases | Life Sciences | Human health and pathology
Journal Article
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, ISSN 0098-7484, 01/2019, Volume 321, Issue 1, pp. 69 - 79
IMPORTANCE Type 2 diabetes is associated with increased cardiovascular (CV) risk. Prior trials have demonstrated CV safety of 3 dipeptidyl peptidase 4 (DPP-4)...
KIDNEY-DISEASE | MORTALITY | GFR DECLINE | END-POINT | SAXAGLIPTIN | HEART-FAILURE | SITAGLIPTIN | DEATH | OUTCOMES | CKD | MEDICINE, GENERAL & INTERNAL | Type 2 diabetes | Usage | Clinical trials | Research | Risk factors | Complications and side effects | Analysis | Placebos | Linagliptin | Dosage and administration | Kidney diseases | Cardiovascular diseases | Drug therapy | Myocardial infarction | End-stage renal disease | Adjudication | Risk | Effects | Incidence | Randomization | Vascular diseases | Safety engineering | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Peptidase | Epidermal growth factor receptors | Diabetes mellitus | Pancreatitis | Health risks | Hypoglycemia | Insulin | Patients | Placebo effect | Prescription drugs | Renal failure | Infarction | Adults | Diabetes | Online First | Original Investigation
KIDNEY-DISEASE | MORTALITY | GFR DECLINE | END-POINT | SAXAGLIPTIN | HEART-FAILURE | SITAGLIPTIN | DEATH | OUTCOMES | CKD | MEDICINE, GENERAL & INTERNAL | Type 2 diabetes | Usage | Clinical trials | Research | Risk factors | Complications and side effects | Analysis | Placebos | Linagliptin | Dosage and administration | Kidney diseases | Cardiovascular diseases | Drug therapy | Myocardial infarction | End-stage renal disease | Adjudication | Risk | Effects | Incidence | Randomization | Vascular diseases | Safety engineering | Hemoglobin | Diabetes mellitus (non-insulin dependent) | Urine | Creatinine | Cerebral infarction | Stroke | Kidneys | Peptidase | Epidermal growth factor receptors | Diabetes mellitus | Pancreatitis | Health risks | Hypoglycemia | Insulin | Patients | Placebo effect | Prescription drugs | Renal failure | Infarction | Adults | Diabetes | Online First | Original Investigation
Journal Article
Gastroenterology, ISSN 0016-5085, 2013, Volume 144, Issue 5, pp. S-1055 - S-1055
Journal Article